

ANNOUNCEMENT

The Board of Directors of Malaysian Genomics Resource Centre Berhad (hereinafter referred to as "MGRC" or "the Company") and its subsidiaries ("the Group") hereby announce the following unaudited results for the quarter ended 30 September 2023.

A PRESENTATION OF RESULTS

I CONDENSED STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME

for the financial period ended	Individual Quarter		Year-to-Date	
	Current Period	Previous Period	Current Period 15 Months	Previous Year**
	30.9.2023 (RM'000)	30.9.2022 (RM'000)	30.9.2023 (RM'000)	30.9.2022 (RM'000)
Continuing operations				
Revenue	2,265	3,812	10,629	N/A
Cost of sales*	(1,121)	(734)	(4,385)	N/A
Gross profit	1,144	3,078	6,244	N/A
Other income	1	43	62	N/A
Marketing and distribution	(556)	(52)	(1,982)	N/A
Finance cost	(25)	(26)	(121)	N/A
Administrative expenses*	(2,053)	(2,196)	(11,743)	N/A
Other expenses - provision of expected credit losses	-	-	(7,538)	N/A
(Loss)/Profit before taxation	(1,489)	847	(15,078)	N/A
Taxation	-	-	(1,153)	N/A
(Loss)/Profit for the period/year	(1,489)	847	(16,231)	N/A
Other comprehensive (loss)/income, net of tax				
<i>Items that will not be reclassified subsequently to profit or loss</i>				
Equity investments measured at fair value through other comprehensive income	-	-	-	N/A
Other comprehensive income for the period/year	-	-	-	N/A
Total comprehensive (loss)/income for the period/year	(1,489)	847	(16,231)	N/A
(Loss)/Profit attributable to:				
Owners of the parent	(1,448)	847	(15,694)	N/A
Non-controlling interests	(41)	-	(537)	N/A
(Loss)/Profit for the period/year	(1,489)	847	(16,231)	N/A
Total comprehensive (loss)/income attributable to:				
Owners of the parent	(1,448)	847	(15,694)	N/A
Non-controlling interests	(41)	-	(537)	N/A
Total comprehensive (loss)/income for the period/year	(1,489)	847	(16,231)	N/A
(Loss)/Earnings per share ("LPS)/EPS") attributable to the equity holders of the Company (sen)				
Basic (LPS)/EPS	(1.07)	0.68	(12.15)	N/A
Diluted (LPS)/EPS	N/A	N/A	N/A	N/A

The unaudited condensed statement of profit and loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 30 June 2022 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

Notes:-

There is no income/expense in relation to other income including investment income, gain/loss on disposal of quoted or unquoted investments or properties, gain/loss on derivatives, or exceptional items, except for as disclosed on the cashflow statement.

* Reclassification of referral fee (Q1 - Q3: RM306,229), royalty fee (Q1 - Q3: RM86,828) and sales commission (Q1 - Q3: RM69,569) from administrative expenses to cost of sales.

**As announced on 25 October 2023, the financial year end of the Group has been changed from 30 June 2023 to 31 December 2023. As such, there will be no comparative financial information available for preceeding year corresponding periods.

N/A - Not Applicable

A PRESENTATION OF RESULTS (cont.)

II CONDENSED STATEMENT OF FINANCIAL POSITION

as at	30.9.2023 (RM'000)	30.6.2022 (RM'000)
ASSETS		
NON-CURRENT ASSETS		
Plant and equipment	3,609	4,305
Intangible assets	4,399	4,950
Right-of-use assets	1,916	1,493
Deferred tax assets	-	1,080
	<u>9,924</u>	<u>11,828</u>
CURRENT ASSETS		
Trade and other receivables	19,446	8,841
Inventories	494	384
Other current assets	111	269
Tax recoverable	56	50
Cash and bank balances	3,685	20,518
	<u>23,792</u>	<u>30,062</u>
TOTAL ASSETS	<u>33,716</u>	<u>41,890</u>
EQUITY AND LIABILITIES		
EQUITY		
Share capital	59,436	52,620
Accumulated losses	(31,267)	(15,573)
Equity attributable to the owners of the company	<u>28,169</u>	<u>37,047</u>
Non-controlling interest	1,384	1,921
TOTAL EQUITY	<u>29,553</u>	<u>38,968</u>
LIABILITIES		
NON-CURRENT LIABILITY		
Lease liabilities	1,702	1,259
	<u>1,702</u>	<u>1,259</u>
CURRENT LIABILITIES		
Trade and other payables	1,893	1,235
Contract liabilities	213	10
Lease liabilities	355	366
Provision for taxation	-	52
	<u>2,461</u>	<u>1,663</u>
TOTAL LIABILITIES	<u>4,163</u>	<u>2,922</u>
TOTAL EQUITY AND LIABILITIES	<u>33,716</u>	<u>41,890</u>
Net assets (RM'000)	28,169	37,047
Net assets per share attributable to equity holders of the Company (sen)	20.53	29.83

The unaudited condensed statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 30 June 2022 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

A PRESENTATION OF RESULTS (cont.)

III CONDENSED STATEMENT OF CHANGES IN EQUITY

	Equity, Total	Non Distributable Share Capital	Fair Value Reserve	Accumulated Losses	Non- Controlling Interest
	(RM'000)	(RM'000)	(RM'000)	(RM'000)	(RM'000)
for the financial year ended 30 June 2023					
Opening balance at 1 July 2022	17,930	40,714	-	(22,784)	-
Total comprehensive income	7,211	-	-	7,211	-
Issuance of new shares, net of share issuance expenses	11,906	11,906	-	-	-
Acquisition of a subsidiary	1,921	-	-	-	1,921
Closing balance at 30 June 2023	38,968	52,620	-	(15,573)	1,921
for the financial period ended 30 September 2023					
Opening balance at 1 July 2023	38,968	52,620	-	(15,573)	1,921
Total comprehensive loss	(16,231)	-	-	(15,694)	(537)
Issuance of new shares, net of share issuance expenses	6,816	6,816	-	-	-
Closing balance at 30 September 2023	29,553	59,436	-	(31,267)	1,384

The unaudited condensed statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 30 June 2022 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

A PRESENTATION OF RESULTS (cont.)

IV CONDENSED STATEMENT OF CASH FLOWS

for the financial period ended	Year-to-Date	
	Current Year	Previous Year**
	30.9.2023 (RM'000)	30.9.2022 (RM'000)
Cash flows from operating activities		
Loss before tax	(15,078)	N/A
Adjustments for:		
Impairment on receivables	7,541	N/A
Amortisation of intangible assets	554	N/A
Depreciation of plant and equipment	1,142	N/A
Depreciation of right-of-use assets	466	N/A
Write down of inventories	58	N/A
Written off of plant and equipment	6	N/A
Interest income	(63)	N/A
Interest expenses	121	N/A
Loss on disposal of plant and equipment	3	N/A
Reversal of impairment loss on trade receivables	(3)	N/A
Operating loss before working capital changes	(5,253)	N/A
Increase in receivables	(17,985)	N/A
Increase in inventories	(168)	N/A
Decrease in payables	862	N/A
Cash used in operations	(22,544)	N/A
Tax paid	(132)	N/A
Interest paid	(121)	N/A
Net cash used in operating activities	(22,797)	N/A
Cash flows from investing activities		
Interest received	63	N/A
Proceeds from disposal of plant and equipment	3	N/A
Purchase of plant and equipment	(458)	N/A
Purchase of intangible assets	(3)	N/A
Investment in quoted shares	-	N/A
Net cash used in investing activities	(395)	N/A
Cash flows from financing activities		
Proceeds from issuance of shares, net of share issuance expenses	6,816	N/A
Repayment of lease liabilities	(457)	N/A
Net cash generated from financing activities	6,359	N/A
Net decrease in cash and cash equivalents	(16,833)	N/A
Cash and cash equivalents at beginning of the period/year	20,518	N/A
Cash and cash equivalents at end of period/year	3,685	N/A

**As announced on 25 October 2023, the financial year end of the Group has been changed from 30 June 2023 to 31 December 2023. As such, there will be no comparative financial information available for preceeding year corresponding periods.

The unaudited condensed statement of cash flows should be read in conjunction with the audited financial statements for the financial year ended 30 June 2023 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

UNAUDITED NOTES TO THE INTERIM FINANCIAL STATEMENTS

B Explanatory Notes Pursuant to MFRS 134

i Basis of Preparation & Changes in Accounting Policies

These condensed consolidated interim financial statements have been prepared in accordance with MGRC 134 Interim Financial Reporting, and Rule 9.22 and Appendix 9B of the ACE Market Listing Requirements ("Listing Requirements") of Bursa Malaysia Securities Berhad ("Bursa Malaysia").

This report should be read in conjunction with the audited financial statements for the financial year ended 30 June 2022 and the accompanying explanatory notes. The significant accounting policies adopted in preparing these condensed consolidated interim financial statements are consistent with those of the audited financial statements for the financial year ended 30 June 2022.

Details of standards, amendments to published standards and interpretations to existing standards that are applicable to the Company with effect from 1 January 2022 or later are provided in the notes to the audited financial statements of the Group for the financial year ended 30 June 2022. The adoption of these MFRSs does not have any material impact on the Group's results and financial position.

ii Auditors' Report on Preceding Annual Financial Statements

The audited financial statements for the financial year ended 30 June 2022 were not qualified.

iii Seasonal and Cyclical Factors

The operations of MGRC were not significantly affected by seasonal and cyclical factors.

iv Material and Unusual Items Affecting Assets, Liabilities, Equity, Net Income or Cash Flow

There were no material and unusual items affecting assets, liabilities, equity, net income or cash flows during the financial period except for disclosed in Notes C (i).

v Material Changes in Estimates

There were no material changes in the estimates that had effect(s) on the financial period.

vi Debt and Equity Securities

There were no issues, repurchases and repayments of debt and equity securities for the financial period to date.

B Explanatory Notes Pursuant to MFRS 134 (cont.)

vii Dividends Paid

There were no dividends paid for the financial period.

viii Segmental Information

MFRS 8 requires identification of reporting segment on the basis of internal reports that are regularly reviewed by the entity's Executive Directors in order to allocate resources to the segment and assess its performance. The management monitors the operating results of the Group as a whole for the purpose of making decisions about resource allocation and performance assessment. Accordingly, the Group has only one reportable segment for the period under review as well as the foreseeable future. Please refer to the financial statements presented in Part A of this announcement.

ix Valuation of Plant and Equipment

There has been no valuation made on any of the Group's plant and equipment during the current financial period under review.

x Subsequent Events

- a. The Company had on 25 October 2023, announced that it had changed its financial year end from 30 June to 31 December. Consequently, the next set of audited financial statements shall be made up from 1 July 2022 to 31 December 2023 covering a period of 18 months and subsequently, the financial year end of the Company shall end on 31 December.
- b. The Company had on 2 November 2023, announced that it has received the approval from the Companies Commission of Malaysia ("CCM") on an extension of time for the Company to hold its Annual General Meeting by 30 June 2024 pursuant to Section 259(2) of the Companies Act 2016.

xi Changes in the Composition of the Group

On 27 July 2023, the Company has incorporated MGRC Holdings Sdn Bhd, a wholly owned subsidiary with paid up share capital of RM2. The principal activity is investment holding.

On the same day, the Company has incorporated Malaysian Immuno Sdn Bhd, a wholly owned subsidiary with paid up share capital of RM2. The principal activity is research, development and commercialisation of immunotherapy products and services.

On 28 July 2023, the Company has incorporated Malaysian Cell Gene Sdn Bhd, a wholly owned subsidiary with paid up share capital of RM2. The principal activity is research, development and commercialisation of cell and gene products and services.

On 31 July 2023, the Company has incorporated Malaysian Cell Gene-Research Sdn Bhd, a wholly owned subsidiary with paid up share capital of RM2. The principal activity is research, development and commercialisation of biopharmaceutical products and services.

On 8 August 2023, the Group incorporated a 70% owned subsidiary, MGRC International Pte. Ltd. In Singapore, which comprising 10 ordinary shares for total cash consideration of SGD10. The principal activity of the Company is distributing healthcare products, beauty products and precision medicine.

All the companies incorporated above still remain dormant as at period end.

B Explanatory Notes Pursuant to MFRS 134 (cont.)

xii Contingent Liabilities or Contingent Assets

There was no contingent liability or contingent asset arising since the last audited statement of financial position as at 30 September 2023.

xiii Capital Commitments

There were no material capital commitments for the purchase of property, plant and equipment that were not provided for in the interim financial statements as at the end of the financial period.

xiv Related Party Transactions

Save as disclosed below, the related party transactions during the financial period to date:-

for the financial period ended		Individual Quarter		Year-to-Date	
		Current Year	Previous Year	Current Year	Previous Year
		30.9.2023	30.9.2022	30.9.2023	30.9.2022
Related Party	Nature of Transaction	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Aquahealth Sdn Bhd	Interest	44	29	204	N/A
Rinani Motorsport Sdn Bhd	Rental of Motor Vehicle	26	-	102	N/A
		70	29	306	N/A

xv Cash and Cash Equivalents

as at	Current Year	Previous Year
	30.9.2023	30.6.2022
	(RM'000)	(RM'000)
Cash on hand and at banks	3,685	1,518
Deposits with licensed banks	-	19,000
	3,685	20,518

xvi Inventories

Inventories written down amounted to RM57,727 during the financial period to date.

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements

These condensed consolidated interim financial statements, for the financial period ended 30 September 2023, have been prepared in accordance with Rule 9.22 and Appendix 9B of the Listing Requirements.

i Performance of the Group

Current Year Quarter End versus Previous Year 1st Quarter

For the quarter ended 30 September 2023, the Group recorded a revenue of RM2.27million, which represents a reduction of RM1.5million as compared to a revenue of RM3.81million for the 1st Quarter in the preceding year. The decrease in revenue due to there are sales from immunotherapy therapies under its biopharmaceutical business in preceding year. However, the Group focus in providing immunotherapy and cell therapies under its biopharmaceutical business which cell therapies contribute the major sales, approximately 78% of the total revenue. The Group will continue strengthening its cell therapies and expand its immunotherapy therapies, organic growth of its genetic screening business and business development activities including opening new territories and developing new products suitable for the fast-moving consumer good (FMCG) market. The Group's effort towards building its biopharmaceutical business is in support of future growth and sustainability.

For the current quarter, the Group recorded a loss before tax of RM1.49million compared to a profit before tax of RM0.85million in the same quarter of the preceding year. The decreased mainly due to lesser revenue generated and the Group involved more events for networking, brand exposure and industry presence.

Current Year-to-Date versus Previous Year-to-Date

As announced on 25 October 2023, the financial year end of the Group has been changed from 30 June 2023 to 31 December 2023. As such, there will be no comparative financial information available for preceding year corresponding periods.

ii Comparison with Preceding Quarter's Results

The comparison of this quarter's results with the preceding quarter is set out below.

	Current Quarter	Preceding Quarter	Variance
for the financial period/year ended	30.9.2023 (RM'000)	30.6.2023 (RM'000)	(RM'000)
Revenue	2,265	2,229	36
Loss before tax	(1,489)	(9,984)	8,495

A higher revenue of RM2.27million was achieved in the current period as compared to the preceding quarter's revenue of RM2.23million, mainly generated from the cell therapies which the Group strengthening its cell therapies.

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

iii Prospects of the Group

Malaysian Genomics Resource Centre Berhad (“MGRC” or “The Group”) is well-positioned to be a leading provider of genetic screening, genome analysis, and biopharmaceutical products and services in Southeast Asia. Utilising its high-throughput sequencing lab, advanced microarray facility, and state-of-the-art BSL-2 cell processing lab that is cGMP approved by MOH for production of cell and gene therapies, including immunotherapy for various types of cancer, the Group is committed to improving access to the latest in precision and personalised healthcare solutions for patients.

The Group’s strategic move to reorganise its operations had led to the formation of four distinct verticals, each focused on addressing the multi-dimensional needs of the healthcare sector which are clinical testing and biotherapeutics, specialised healthcare services, specialised manufacturing and healthcare artificial intelligence and big data.

The Group’s broad market access and diverse product portfolio have never been greater than they are today. An integral part of this requires increasing the breadth and depth of distribution networks for the Group’s products and services. To this end, MGRC seeks and engages with strategic partners across Southeast Asia, the Middle-East North Africa region and the United States. To capitalise on its growing distribution network, the Group is applying its genomics and pharmaceutical expertise to develop a portfolio of products for the fast-moving consumer goods market. This includes novel ingredients and finished products for cosmeceuticals, wound healing, and genetic-based fitness improvement programs.

In Malaysia, the Group works closely with private hospitals and the Ministry of Health to improve access to its immunotherapies. On 6 September 2023, the Group entered into a Strategic Collaboration Agreement with Yayasan Kanser Malaysia (“YKM”) to form a partnership aims to elevate cancer awareness and early detection by merging YKM’s community centric educational programmes with the Group advanced genomic and immunotherapy services. The Group also entered Memorandum of Understanding with AntChain Technology Pte. Ltd. (“ACT”) to integrate the Group’s expertise in personalised and precision medicine with ACT’s technological acumen, particularly in blockchain traceability.

iv Variance from Profit Forecast

The Group did not publish any profit forecast.

v Taxation

The taxation for the current quarter and period ended are as follows:

for the financial period/year ended	Individual Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year**
	30.9.2023	30.9.2022	30.9.2023	30.9.2022
	RM'000	RM'000	RM'000	RM'000
Income tax				
Undertaken in prior year	-	-	(59)	N/A
Current year	-	-	(14)	N/A
	-	-	(73)	N/A
Deferred tax				
Origination and reversal of temporary differences	-	-	(1,080)	N/A
	-	-	(1,153)	N/A

**As announced on 25 October 2023, the financial year end of the Group has been changed from 30 June 2023 to 31 December 2023. As such, there will be no comparative financial information available for preceding year corresponding periods.

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

vi Status of Corporate Proposal

There is no corporate proposal announced but not completed as at the date of this announcement, other than multiple proposal announced on 17 July 2023 which included long term incentive plan, proposed share capital reduction and proposed change of name, but has not been completed as at date of this announcement.

vii Material Litigations

According to announcement on 26 October 2023, the Company has on 25 October 2023, received a notice from an Independent Non-Executive Director (“INED”) of the Company, on his intention to apply for leave to commence derivative proceedings pursuant to Section 347 and Section 348(2) of the Companies Act 2016, in the name of the Company against individual Directors and Management of the Company (collectively referred to as “Parties”), for alleged breaches of fiduciary duties by the Parties in relation to the transactions involving the Company and its subsidiaries with external parties.

Subsequently, the Company has on 30 October 2023 received an Originating Summons (“OS”) dated 26 October 2023 from the abovenamed INED, Aswath A/L Ramakrishnan (“Applicant”) via his solicitors, Messrs. Ahmad Deniel Ruben & Co at the High Court of Malaya at Shah Alam against the Company (“Respondent”) pursuant to the abovementioned Notice.

OS was initiated by Aswath A/L Ramakrishnan (“Applicant”) against Malaysian Genomics Resource Centre Berhad (“MGRC” or “Respondent”) via filing of the relevant cause papers dated 26 October 2023 at the Malaya High Court at Shah Alam on the following actions in relation to certain transactions (“Transactions”) entered into by the Company and its subsidiaries with Rinani Renal Berhad, Dynamic Prestige Consultancy Sdn Bhd and Rinani Genotec Sdn Bhd (now known as Genotec Sdn Bhd), in which the details have been announced to Bursa Malaysia Securities Berhad on 8 November 2023:

- (a) For the statutory notice pursuant to Section 348(2) of the Companies Act 2016 to be abridged;
- (b) To commence a derivative action and/or proceedings against all the Directors of the Company and officers of the Company on alleged breach of fiduciary duties;
- (c) To appoint an independent auditor by the Applicant to conduct an investigation on the Respondent including the administration and operational matters of the Respondent;
- (d) To obtain full cooperation from all the parties including agent, directors, officers, employees and other relevant representatives in the course of the investigation;
- (e) Costs; and
- (f) Such further or other relief as the Honorable Court deems just and fit.

Pursuant to the OS, the claims were made against the Board of Directors and the relevant officers of the Company in breaching their fiduciary duties for the following matters:

- (i) in obtaining approval from its Board of Directors prior executing the Transactions;
- (ii) the Directors have failed to exercise their duty of supervision of control and failed to make the necessary disclosure at the material time;
- (iii) the Board of Directors have voted to change the financial year end of the Respondent instead of resolving the audit issues highlighted by the external auditors of MGRC; and
- (iv) lack of management and disclosure in the operational and financial management of the Respondent.

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

vii Material Litigations (cont.)

Case management of the matter by way of e-review held on 23 November 2023, the hearing date on the matter will be held before the Shah Alam High Court on 3 January 2024.

The Company will be obtaining the necessary legal advice from solicitors with regards to the above OS filed by the Applicant. Apart from the potential costs which may be awarded against the Company and the corresponding legal costs, other costs in relation thereto have yet to be determined and the Board of Directors viewed that there will not be any operational impact to the Company.

viii Dividends

There were no dividends paid for the financial period.

ix Trade receivables

The ageing analysis of the Group's trade receivables is as follows:-

	30.9.2023 (RM'000)
Not past due	592
Past due	
- 1 to 30 days	432
- 31 to 60 days	306
- 61 to 90 days	243
- more than 90 days	10,081
	<u>11,062</u>
Gross	11,654
Impaired	<u>(7,715)</u>
Net	<u>3,939</u>

Receivables that are past due but not impaired

The Group believes that no further impairment allowance is necessary in respect of these trade receivables. They are substantially companies with good collection track record and no recent history of default.

x (LPS)/EPS

- a) **Basic (LPS)/EPS** Computed by dividing the profit after tax, attributable to owners of the parent for the financial period by the weighted average of the number of ordinary shares in issue during the period.

Basic (LPS)/EPS	Individual Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year**
	30.9.2023	30.9.2022	30.9.2023	30.9.2022
for the financial period ended				
(Loss)/Profit after tax, attributable to owners of the parent (RM'000)	(1,448)	847	(15,694)	N/A
Weighted average number of ordinary shares in issue ('000)	135,384	124,210	129,138	N/A
Basic (LPS)/EPS (sen)	<u>(1.07)</u>	<u>0.68</u>	<u>(12.15)</u>	<u>N/A</u>

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

x (LPS)/EPS (cont.)

b) **Diluted (LPS)/EPS.** The Company does not have any convertible shares or convertible financial instruments for the current financial quarter and financial period to date.

**As announced on 25 October 2023, the financial year end of the Group has been changed from 30 June 2023 to 31 December 2023. As such, there will be no comparative financial information available for preceeding year corresponding periods.

xi Status of Utilisation of Proceeds

a)	Proposed utilisation of proceeds from private placement	Proposed utilisation timeframe	Proposed Utilisation (RM'000)	Variation (#) (RM'000)	Actual Utilisation (RM'000)	Balance of Amount Allocated (RM'000)
	Expenses for the private placement	Immediate	361	-	(361)	-
	Working capital	Within 24 months from receipt of funds	23,834	(5,800)	(18,034)	-
	Haemodialysis business	Within 24 months from 28 June 2022	-	5,500	(5,500)	-
	Capital expenditure	Within 24 months from 28 June 2022	-	300	(178)	122
			<u>24,195</u>	<u>-</u>	<u>(24,073)</u>	<u>122</u>

Pursuant to the variation of purpose of utilisation of proceeds as announced by the Company on 28 June 2022.

b)	Proposed utilisation of proceeds from private placement	Proposed utilisation timeframe	Proposed Utilisation (RM'000)	Variation (RM'000)	Actual Utilisation (RM'000)	Balance of Amount Allocated (RM'000)
	Future viable investment	Within 24 months from completion	4,033	(60)	-	3,973
	Purchase of equipment	Within 24 months from completion	-	-	-	-
	Estimated expenses	Upon completion	-	60	(60)	-
			<u>4,033</u>	<u>-</u>	<u>(60)</u>	<u>3,973</u>

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

xi Status of Utilisation of Proceeds (cont.)

c) Proposed utilisation of proceeds from private placement	Proposed utilisation timeframe	Proposed Utilisation (RM'000)	Variation (RM'000)	Actual Utilisation (RM'000)	Balance of Amount (RM'000)
Working capital	Within 12 months from listing	2,720	92	(1,268)	1,544
Estimated expenses	Upon completion	150	(92)	(58)	-
		<u>2,870</u>	<u>-</u>	<u>(1,326)</u>	<u>1,544</u>

xii Authorisation for Issue

The interim financial statements were authorised for issue by the Board of Directors of MGRC in accordance with a Resolution of the Directors dated 28 November 2023.